Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Epidemiology, aetiology, and management of ischaemic stroke in young adults.

Ekker MS, Boot EM, Singhal AB, Tan KS, Debette S, Tuladhar AM, de Leeuw FE.

Lancet Neurol. 2018 Sep;17(9):790-801. doi: 10.1016/S1474-4422(18)30233-3. Review.

PMID:
30129475
2.

A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson's disease and schizophrenia.

Sumitomo A, Horike K, Hirai K, Butcher N, Boot E, Sakurai T, Nucifora FC Jr, Bassett AS, Sawa A, Tomoda T.

Sci Adv. 2018 Aug 15;4(8):eaar6637. doi: 10.1126/sciadv.aar6637. eCollection 2018 Aug.

3.

Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia.

Fiksinski AM, Breetvelt EJ, Lee YJ, Boot E, Butcher N, Palmer L, Chow EWC, Kahn RS, Vorstman JAS, Bassett AS.

Psychol Med. 2018 Aug 1:1-8. doi: 10.1017/S0033291718001824. [Epub ahead of print]

PMID:
30064532
4.

Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Butcher NJ, Boot E, Lang AE, Andrade D, Vorstman J, McDonald-McGinn D, Bassett AS.

Am J Med Genet A. 2018 May 19. doi: 10.1002/ajmg.a.38708. [Epub ahead of print]

PMID:
29777584
5.

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

Boot E, Butcher NJ, Udow S, Marras C, Mok KY, Kaneko S, Barrett MJ, Prontera P, Berman BD, Masellis M, Dufournet B, Nguyen K, Charles P, Mutez E, Danaila T, Jacquette A, Colin O, Drapier S, Borg M, Fiksinski AM, Vergaelen E, Swillen A, Vogels A, Plate A, Perandones C, Gasser T, Clerinx K, Bourdain F, Mills K, Williams NM, Wood NW, Booij J, Lang AE, Bassett AS; International Research Group on 22q11.2DS-associated Parkinson's Disease.

Neurology. 2018 Jun 5;90(23):e2059-e2067. doi: 10.1212/WNL.0000000000005660. Epub 2018 May 11.

6.

Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Palmer LD, Butcher NJ, Boot E, Hodgkinson KA, Heung T, Chow EWC, Guna A, Crowley TB, Zackai E, McDonald-McGinn DM, Bassett AS.

Am J Med Genet A. 2018 Apr;176(4):936-944. doi: 10.1002/ajmg.a.38645.

PMID:
29575622
7.

Non-pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review.

Buijs PCM, Bassett AS, Boot E.

Am J Med Genet A. 2018 Aug;176(8):1742-1747. doi: 10.1002/ajmg.a.38612. Epub 2018 Jan 24. Review.

PMID:
29363845
8.

Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis.

Vingerhoets C, Bloemen OJN, Boot E, Bakker G, de Koning MB, da Silva Alves F, Booij J, van Amelsvoort TAMJ.

Psychiatry Res Neuroimaging. 2018 Feb 28;272:65-70. doi: 10.1016/j.pscychresns.2017.11.014. Epub 2017 Nov 21.

PMID:
29174435
9.

[Off-label prescription of antipsychotics].

Boot E.

Ned Tijdschr Geneeskd. 2017;161:D2035. Dutch.

PMID:
29171377
10.

Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.

Bassett AS, Lowther C, Merico D, Costain G, Chow EWC, van Amelsvoort T, McDonald-McGinn D, Gur RE, Swillen A, Van den Bree M, Murphy K, Gothelf D, Bearden CE, Eliez S, Kates W, Philip N, Sashi V, Campbell L, Vorstman J, Cubells J, Repetto GM, Simon T, Boot E, Heung T, Evers R, Vingerhoets C, van Duin E, Zackai E, Vergaelen E, Devriendt K, Vermeesch JR, Owen M, Murphy C, Michaelovosky E, Kushan L, Schneider M, Fremont W, Busa T, Hooper S, McCabe K, Duijff S, Isaev K, Pellecchia G, Wei J, Gazzellone MJ, Scherer SW, Emanuel BS, Guo T, Morrow BE, Marshall CR; International 22q11.2DS Brain and Behavior Consortium.

Am J Psychiatry. 2017 Nov 1;174(11):1054-1063. doi: 10.1176/appi.ajp.2017.16121417. Epub 2017 Jul 28.

11.

Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria.

Boot E, Hollak CEM, Huijbregts SCJ, Jahja R, van Vliet D, Nederveen AJ, Nieman DH, Bosch AM, Bour LJ, Bakermans AJ, Abeling NGGM, Bassett AS, van Amelsvoort TAMJ, van Spronsen FJ, Booij J.

Psychol Med. 2017 May 29:1-12. doi: 10.1017/S0033291717001398. [Epub ahead of print]

PMID:
28552082
12.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EWC, Masellis M, Strafella AP, Lang AE, Bassett AS.

Brain. 2017 May 1;140(5):1371-1383. doi: 10.1093/brain/awx053.

PMID:
28369257
13.

Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.

Van L, Boot E, Bassett AS.

Curr Opin Psychiatry. 2017 May;30(3):191-196. doi: 10.1097/YCO.0000000000000324. Review.

PMID:
28230630
14.

[A woman with reversible encephalopathy].

Boot EM, Hanny KH, Meijer FJ, van Eijk JJ.

Ned Tijdschr Geneeskd. 2017;161:D690. Dutch.

PMID:
28198344
15.

Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome.

Bakker G, Caan MW, Vingerhoets WA, da Silva-Alves F, de Koning M, Boot E, Nieman DH, de Haan L, Bloemen OJ, Booij J, van Amelsvoort TA.

PLoS One. 2016 Nov 9;11(11):e0159928. doi: 10.1371/journal.pone.0159928. eCollection 2016.

16.

Rapporteur summaries of plenary, symposia, and oral sessions from the XXIIIrd World Congress of Psychiatric Genetics Meeting in Toronto, Canada, 16-20 October 2015.

Zai G, Alberry B, Arloth J, Bánlaki Z, Bares C, Boot E, Camilo C, Chadha K, Chen Q, Cole CB, Cost KT, Crow M, Ekpor I, Fischer SB, Flatau L, Gagliano S, Kirli U, Kukshal P, Labrie V, Lang M, Lett TA, Maffioletti E, Maier R, Mihaljevic M, Mittal K, Monson ET, O'Brien NL, Østergaard SD, Ovenden E, Patel S, Peterson RE, Pouget JG, Rovaris DL, Seaman L, Shankarappa B, Tsetsos F, Vereczkei A, Wang C, Xulu K, Yuen RK, Zhao J, Zai CC, Kennedy JL.

Psychiatr Genet. 2016 Dec;26(6):229-257.

17.

Obesity in adults with 22q11.2 deletion syndrome.

Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, Silversides CK, Bassett AS.

Genet Med. 2017 Feb;19(2):204-208. doi: 10.1038/gim.2016.98. Epub 2016 Aug 18.

18.

Corrigendum to "Cardiac sympathetic activity in 22q11.2 deletion syndrome" [Int. J. Cardiol. 212 (2016) 346-351].

Verschure DO, Boot E, van Amelsvoort TA, Booij J, van Eck-Smit BLF, Somsen GA, Verberne HJ.

Int J Cardiol. 2016 Nov 1;222:1141. doi: 10.1016/j.ijcard.2016.06.055. Epub 2016 Jun 30. No abstract available.

PMID:
27373741
19.

Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis.

Bakker G, Caan MW, Schluter RS, Bloemen OJ, da Silva-Alves F, de Koning MB, Boot E, Vingerhoets WA, Nieman DH, de Haan L, Booij J, van Amelsvoort TA.

Psychol Med. 2016 Aug;46(11):2299-311. doi: 10.1017/S0033291716000970. Epub 2016 May 19.

PMID:
27193339
20.

Cardiac sympathetic activity in 22q11.2 deletion syndrome.

Verschure DO, Boot E, van Amelsvoort TA, Booij J, van Eck-Smit BL, Somsen GA, Verberne HJ.

Int J Cardiol. 2016 Jun 1;212:346-51. doi: 10.1016/j.ijcard.2016.03.185. Epub 2016 Mar 25. Erratum in: Int J Cardiol. 2016 Nov 1;222:1141.

PMID:
27057952
21.

Internet Safety Issues for Adolescents and Adults with Intellectual Disabilities.

Buijs PCM, Boot E, Shugar A, Fung WLA, Bassett AS.

J Appl Res Intellect Disabil. 2017 Mar;30(2):416-418. doi: 10.1111/jar.12250. Epub 2016 Feb 23.

PMID:
26914835
22.

Pharmacological treatment of 22q11.2 deletion syndrome-related psychoses.

Boot E, Butcher NJ, Vorstman JA, van Amelsvoort TA, Fung WL, Bassett AS.

Pharmacopsychiatry. 2015 Sep;48(6):219-20. doi: 10.1055/s-0035-1554645. Epub 2015 Jun 19.

PMID:
26091278
23.

PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

de Koning MB, van Duin ED, Boot E, Bloemen OJ, Bakker JA, Abel KM, van Amelsvoort TA.

Psychopharmacology (Berl). 2015 Sep;232(17):3111-22. doi: 10.1007/s00213-015-3971-5. Epub 2015 Jun 12.

PMID:
26068888
24.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome.

Boot E, Butcher NJ, van Amelsvoort TA, Lang AE, Marras C, Pondal M, Andrade DM, Fung WL, Bassett AS.

Am J Med Genet A. 2015 Mar;167A(3):639-45. doi: 10.1002/ajmg.a.36928. Epub 2015 Feb 13.

25.

Parkinsonism in phenylketonuria: a consequence of dopamine depletion?

Velema M, Boot E, Engelen M, Hollak C.

JIMD Rep. 2015;20:35-8. doi: 10.1007/8904_2014_386. Epub 2015 Jan 23.

26.

Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, Chung B, Cytrynbaum C, Faghfoury H, Fishman L, García-Miñaúr S, George S, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS.

Genet Med. 2015 Aug;17(8):599-609. doi: 10.1038/gim.2014.175. Epub 2015 Jan 8. Review.

27.

Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase.

Zevenbergen C, Klootwijk W, Peeters RP, Medici M, de Rijke YB, Huisman SA, Goeman H, Boot E, de Kuijper G, de Waal KH, Meima ME, Larsen PR, Visser TJ, Visser WE.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2429-36. doi: 10.1210/jc.2014-2281. Epub 2014 Aug 20.

PMID:
25140401
28.

Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome.

Evers LJ, Curfs LM, Bakker JA, Boot E, da Silva Alves F, Abeling N, Bierau J, Drukker M, van Amelsvoort TA.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1159-65. doi: 10.1017/S1461145714000376. Epub 2014 Apr 8.

PMID:
24713114
29.

Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Schneider M, Debbané M, Bassett AS, Chow EW, Fung WL, van den Bree M, Owen M, Murphy KC, Niarchou M, Kates WR, Antshel KM, Fremont W, McDonald-McGinn DM, Gur RE, Zackai EH, Vorstman J, Duijff SN, Klaassen PW, Swillen A, Gothelf D, Green T, Weizman A, Van Amelsvoort T, Evers L, Boot E, Shashi V, Hooper SR, Bearden CE, Jalbrzikowski M, Armando M, Vicari S, Murphy DG, Ousley O, Campbell LE, Simon TJ, Eliez S; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome.

Am J Psychiatry. 2014 Jun;171(6):627-39. Review.

30.

Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes.

Delio M, Guo T, McDonald-McGinn DM, Zackai E, Herman S, Kaminetzky M, Higgins AM, Coleman K, Chow C, Jalbrzikowski M, Bearden CE, Bailey A, Vangkilde A, Olsen L, Olesen C, Skovby F, Werge TM, Templin L, Busa T, Philip N, Swillen A, Vermeesch JR, Devriendt K, Schneider M, Dahoun S, Eliez S, Schoch K, Hooper SR, Shashi V, Samanich J, Marion R, van Amelsvoort T, Boot E, Klaassen P, Duijff SN, Vorstman J, Yuen T, Silversides C, Chow E, Bassett A, Frisch A, Weizman A, Gothelf D, Niarchou M, van den Bree M, Owen MJ, Suñer DH, Andreo JR, Armando M, Vicari S, Digilio MC, Auton A, Kates WR, Wang T, Shprintzen RJ, Emanuel BS, Morrow BE.

Am J Hum Genet. 2013 Mar 7;92(3):439-47. doi: 10.1016/j.ajhg.2013.01.018. Epub 2013 Feb 28. Erratum in: Am J Hum Genet. 2013 Apr 4;92(4):637. Jarlbrzkowski, Maria [corrected to Jalbrzikowski, Maria].

31.

Neuroimaging correlates of 22q11.2 deletion syndrome: implications for schizophrenia research.

Boot E, van Amelsvoort TA.

Curr Top Med Chem. 2012;12(21):2303-13. Review.

PMID:
23279171
32.

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.

Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP.

Vaccine. 2013 Feb 4;31(7):1065-71. doi: 10.1016/j.vaccine.2012.12.031. Epub 2012 Dec 27.

PMID:
23273968
33.

Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome.

de Koning MB, Boot E, Bloemen OJ, van Duin ED, Abel KM, de Haan L, Linszen DH, van Amelsvoort TA.

J Psychopharmacol. 2012 Dec;26(12):1548-60. doi: 10.1177/0269881112456610. Epub 2012 Sep 5.

PMID:
22952320
34.

Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome.

van Beveren NJ, Krab LC, Swagemakers S, Buitendijk GH, Boot E, van der Spek P, Elgersma Y, van Amelsvoort TA.

PLoS One. 2012;7(3):e33473. doi: 10.1371/journal.pone.0033473. Epub 2012 Mar 22. Erratum in: PLoS One. 2012;7(4): doi/10.1371/annotation/d80f4e7d-5e96-41da-9dae-717b0d0d3c60. Buitendijk, Gabriella [corrected to Buitendijk, Gabriëlle H S]..

35.

Overexpression of chromosome 15q11-q13 gene products: a risk factor for schizophrenia and associated psychoses?

Boot E, Kant SG, Otter M, Cohen D, Nabanizadeh A, Baas RW.

Am J Psychiatry. 2012 Jan;169(1):96-7; author reply 97. doi: 10.1176/appi.ajp.2011.11091382. No abstract available.

PMID:
22223014
36.

Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects.

de Weijer BA, van de Giessen E, van Amelsvoort TA, Boot E, Braak B, Janssen IM, van de Laar A, Fliers E, Serlie MJ, Booij J.

EJNMMI Res. 2011 Dec 16;1(1):37. doi: 10.1186/2191-219X-1-37.

37.

White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia.

da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E, Nederveen A, de Haan L, Linszen D, van Amelsvoort T.

Schizophr Res. 2011 Oct;132(1):75-83. doi: 10.1016/j.schres.2011.07.017. Epub 2011 Aug 9.

38.

Proton magnetic resonance spectroscopy in 22q11 deletion syndrome.

da Silva Alves F, Boot E, Schmitz N, Nederveen A, Vorstman J, Lavini C, Pouwels PJ, de Haan L, Linszen D, van Amelsvoort T.

PLoS One. 2011;6(6):e21685. doi: 10.1371/journal.pone.0021685. Epub 2011 Jun 30. Erratum in: PLoS One. 2011;6(8). doi: 10.1371/annotation/805ba3f5-0fd7-41f9-bc2c-31ebf507f05b. Pouwels, Petra [corrected to Pouwels, Petra J].

39.

COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome.

Boot E, Booij J, Zinkstok JR, Baas F, Swillen A, Owen MJ, Murphy DG, Murphy KC, Linszen DH, Van Amelsvoort TA.

Synapse. 2011 Sep;65(9):967-70. doi: 10.1002/syn.20932. Epub 2011 Apr 26.

PMID:
21465565
40.

Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology.

Boot E, Booij J, Abeling N, Meijer J, da Silva Alves F, Zinkstok J, Baas F, Linszen D, van Amelsvoort T.

J Psychopharmacol. 2011 Jul;25(7):888-95. doi: 10.1177/0269881111400644. Epub 2011 Mar 29.

PMID:
21447540
41.

Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT.

Booij J, Boot E, van Eeden S, van Amelsvoort T.

Clin Nucl Med. 2011 Feb;36(2):148-9. doi: 10.1097/RLU.0b013e318203be54.

PMID:
21220985
42.

Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging.

Booij J, van Amelsvoort T, Boot E.

Am J Med Genet A. 2010 Nov;152A(11):2937-8. doi: 10.1002/ajmg.a.33665. No abstract available.

PMID:
20949509
43.

Striatal D₂ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study.

Boot E, Booij J, Zinkstok JR, de Haan L, Linszen DH, Baas F, van Amelsvoort TA.

J Psychopharmacol. 2010 Oct;24(10):1525-31. doi: 10.1177/0269881109104854. Epub 2009 Apr 30.

PMID:
19406852
44.

IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis.

Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, Parren PW, van de Winkel JG.

J Immunol. 2008 Jul 1;181(1):669-79.

45.

AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.

Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1350-6. doi: 10.1007/s00259-008-0739-8. Epub 2008 Feb 19.

46.

Genetic vaccination: one-shot shopping for immediate and sustained protection.

Boot EP, Parren PW.

Mol Ther. 2008 Jan;16(1):6-7. No abstract available.

47.

Identification and monitoring of effector and regulatory T cells during experimental arthritis based on differential expression of CD25 and CD134.

Nolte-'t Hoen EN, Boot EP, Wagenaar-Hilbers JP, van Bilsen JH, Arkesteijn GJ, Storm G, Everse LA, van Eden W, Wauben MH.

J Leukoc Biol. 2008 Jan;83(1):112-21. Epub 2007 Oct 10.

PMID:
17928458
48.

Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome.

Boot E, Booij J, Zinkstok J, Abeling N, de Haan L, Baas F, Linszen D, van Amelsvoort T.

Neuropsychopharmacology. 2008 May;33(6):1252-8. Epub 2007 Jul 25.

49.

CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.

Boot EP, Koning GA, Storm G, Wagenaar-Hilbers JP, van Eden W, Everse LA, Wauben MH.

Arthritis Res Ther. 2005;7(3):R604-15. Epub 2005 Mar 21.

50.

Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.

Nolte-'t Hoen EN, Wagenaar-Hilbers JP, Boot EP, Lin CH, Arkesteijn GJ, van Eden W, Taams LS, Wauben MH.

Eur J Immunol. 2004 Nov;34(11):3016-27.

Supplemental Content

Support Center